A Synergistic Therapy With Antioxidant and Anti‐VEGF: Toward its Safe and Effective Elimination for Corneal Neovascularization
Advanced Healthcare Materials · 2024-02 · 13 (5)
DOI: 10.1002/adhm.202302192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 08.12.2023. Verfasst von Huimin Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Xiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China. Hauptthemen laut MEDLINE: Corneal Neovascularization. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Corneal neovascularization (CNV) is one of the leading causes of blindness in the world. In clinical practice; however, it remains a challenge to achieve a noninvasive and safe treatment. Herein, a biocompatible shell with excellent antioxidant and antivascularity is prepared by co‐assembly of epigallocatechin gallate/gallic acid and Cu (II). After loading glucose oxidase (GO x ) inside, the shell is modified with dimeric DPA‐Zn for codelivering vascular endothelial growth factor (VEGF) small interfering RNA (VEGF‐siRNA). Meanwhile, the Arg‐Gly‐Asp peptide (RGD) peptide‐engineered cell membranes coating improves angiogenesis‐targeting and is biocompatible for the multifunctional nanomedicine (CEGs/RGD). After eye drops administration, CEGs/RGD targets enrichment in neovascularization and CEGs NPs enter cells. Then, the inner GO x consumes glucose with a decrease in local pH, which in turn leads to the release of EGCE and VEGF‐siRNA. As a result, the nanomedicines significantly reduce angiogenesis and inhibit CNV formation through synergistic effect of antioxidant and antivascular via down‐regulation of cluster of differentiation 31 and VEGF. The nanomedicine represents a safe and efficient CNV treatment through the combined effect of antioxidant/gene, which provides important theoretical and clinical significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
- Department of Pharmacy, Xiamen Medical College, Xiamen, 361023, China.
- State Key Laboratory of Physical Chemistry of Solid Surfaces, The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, Chi…
- Shen Zhen Research Institute of Xiamen University, Xiamen University, Shenzhen, 518057, China.
ORCID-Profile: Yiming Wu, Chengchao Chu
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Science and Technology Program
- National College Student Innovation and Entrepreneurship Training Program
- Science Foundation of Fujian Province
Zitieren
APA
Zhu, H., Ye, J., Wu, Y., Cheng, Y., Su, M., Dai, Q., Han, Y., Pan, J., Wu, Z., Chen, C., Qiu, C., Li, W., Liu, G., & Chu, C. (2024). A Synergistic Therapy With Antioxidant and Anti‐VEGF: Toward its Safe and Effective Elimination for Corneal Neovascularization. Advanced Healthcare Materials, 13(5). https://doi.org/10.1002/adhm.202302192
Vancouver
Zhu H, Ye J, Wu Y, Cheng Y, Su M, Dai Q, et al. A Synergistic Therapy With Antioxidant and Anti‐VEGF: Toward its Safe and Effective Elimination for Corneal Neovascularization. Advanced Healthcare Materials. 2024;13(5). doi:10.1002/adhm.202302192
BibTeX
@article{Zhu2024,
author = {Zhu, Huimin and Ye, Jinfa and Wu, Yiming and Cheng, Yuhang and Su, Min and Dai, Qixuan and Han, Yun and Pan, Jintao and Wu, Zhenyu and Chen, Chuan and Qiu, Chenyue and Li, Wei and Liu, Gang and Chu, Chengchao},
title = {A Synergistic Therapy With Antioxidant and Anti‐VEGF: Toward its Safe and Effective Elimination for Corneal Neovascularization},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {5},
doi = {10.1002/adhm.202302192}
}
EUVIMED